ERNEWA
Dead / Abandoned — Abandoned — after publication (as of 09 May 2017)
What this means for you
This application is over — abandoned 08 May 2017. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 86883630
- Mark type
- Stylized text
- Filed
- 22 Jan 2016
- Published for opposition
- 31 May 2016
- Abandoned
- 08 May 2017
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Owner
- Forest Laboratories, LLC, Parsippany, NJ, US
- Forest Laboratories, LLC, Parsippany, NJ, US
Prosecution history
- 09 May 2017 — ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
- 09 May 2017 — ABANDONMENT - AFTER PUBLICATION
- 08 May 2017 — TEAS EXPRESS ABANDONMENT RECEIVED
- 07 Jan 2017 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Jan 2017 — SOU EXTENSION 1 GRANTED
- 05 Jan 2017 — SOU EXTENSION 1 FILED
- 05 Jan 2017 — SOU TEAS EXTENSION RECEIVED
- 26 Jul 2016 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 31 May 2016 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 May 2016 — PUBLISHED FOR OPPOSITION
- 11 May 2016 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 26 Apr 2016 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 19 Apr 2016 — ASSIGNED TO LIE
- 02 Apr 2016 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Apr 2016 — EXAMINER'S AMENDMENT ENTERED